Kornimate/medical-research-clean huggingface dataset:
role of ablative radiotherapy in the management of metastatic disease: a patient data registry

Conditions: Oligometastasis; Metastatic Cancer

Summary: the purpose of this study is to provide a registry of participants in order to assess the acute adverse event rates following ablative radiotherapy for metastatic disease.


Eligibility criteria:
inclusion criteria: * age ≥ 18 years of age * radiographic evidence of metastatic disease (may include oligoprogression, oligorecurrence or oligometastasis) at the time of study enrollment * planned to receive, currently receiving, or have completed hypofractionated image guided radiotherapy (ablative radiotherapy) to an extracranial site(s) * patient must sign study-specific informed consent exclusion criteria: • none

Keywords: ablative radiotherapy
substance abuse self-help group referral: outcomes and services use

Conditions: Substance Use Disorders

Summary: self-help groups (shgs) have become an important component of the system of care for patients with substance use disorders (suds). sud patients' participation in shgs has been linked to lower relapse rates and less use of additional treatment services.

background: self-help groups (shgs) have become an important component of the system of care for patients with substance use disorders (suds). sud patients' participation in shgs has been linked to lower relapse rates and less use of additional treatment services. objectives: the first objective was to implement and validate procedures to help counselors make effective referrals to shgs for sud patients. this project randomly assigned sud outpatients to a standard referral or an intensive referral condition. we are determining the extent to which intensive referral increased patients' shg attendance and involvement in comparison to standard referral. the second objective is to determine whether patients who received intensive referral to shgs have better substance use and functioning outcomes over the 1-year follow-up period, and less use of formal treatment services, thereby reducing costs for va, than those who received standard referral. the long-term goal is to develop and implement guidelines to facilitate sud patients' participation in shgs and thereby improve their quality of life and decrease their use of va's specialized sud treatment services. methods: this project used a randomized design in which 345 patients entering va outpatient sud treatment were randomly assigned to either standard or intensive referral to shgs. standard referral consisted of the counselor recommending shg participation. the keys to intensive referral included the counselor facilitating direct contact between the patient and a member of the shg, and counselor follow-up on the recommendation for self-help. patients were followed at 6 months and 1 year to determine whether intensive referral resulted in more self-help attendance and involvement; in better substance use and functioning outcomes (using the addiction severity index); and in less use of va services and lower treatment costs (using methods of the va health economics resource center). to make these determinations, we are conducting analyses at each follow-up, and then will use hierarchical linear modeling to examine the benefits of intensive referral over time. status: project work is ongoing.

Eligibility criteria:
inclusion criteria: consecutive substance use disorder outpatients at va pa hcs and is not cognitively impaired. exclusion criteria: cognitive impairment

Keywords: self-help groups referral and consultation
temozolomide in treating patients with low-grade glioma

Conditions: CNS Tumor, Adult

Summary: rationale: drugs used in chemotherapy, such as temozolomide, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. purpose: this phase ii trial is studying how well temozolomide works in treating patients with supratentorial low-grade glioma.

objectives: primary * determine the efficacy of temozolomide, defined as response rate (complete and partial response), in patients with supratentorial mixed low-grade glioma. secondary * assess the safety profile of temozolomide in patients with supratentorial low-grade glioma. * assess the time to tumor progression in patients treated with temozolomide. outline: patients receive oral temozolomide once daily on days 1-5. treatment repeats every 28 days for up to 12 courses in the absence of disease progression or unacceptable toxicity. after completion of study treatment, patients are followed every 3 months for 1 year, every 4 months for 1 year, every 6 months for 1 year, and then annually thereafter. projected accrual: a total of 120 patients will be accrued for this study.

Eligibility criteria:
disease characteristics: * histologically proven supratentorial low-grade (grade ii) glioma of any of the following histologic subtypes: * oligodendroglioma * astrocytoma * oligoastrocytoma * has undergone surgical resection or biopsy within 35 days after diagnosis of low-grade glioma * study treatment must begin between 14 days and 4 months after surgical resection or biopsy * evaluable disease by gadolinium-mri patient characteristics: * karnofsky performance status 60-100% * absolute neutrophil count ≥ 1,500/mm\^3 * platelet count ≥ 100,000/mm\^3 * hemoglobin ≥ 10 g/dl * creatinine \< 1.5 times upper limit of normal (uln) * bun \< 1.5 times uln * bilirubin \< 1.5 times uln * sgot \< 2.5 times uln * alkaline phosphatase \< 2 times uln * life expectancy \> 12 weeks * no nonmalignant systemic disease resulting in the patient being a poor medical risk * no acute infection requiring intravenous antibiotics * no frequent vomiting or medical condition that would interfere with oral medication intake (e.g., partial bowel obstruction) * no other concurrent malignancies except surgically cured carcinoma in situ of the cervix or basal cell or squamous cell carcinoma of the skin * prior malignancies must be in remission for ≥ 5 years * no known hiv positivity * no aids-related illness * not pregnant or nursing * negative pregnancy test * fertile patients must use effective contraception prior concurrent therapy: * see disease characteristics * no prior radiotherapy, interstitial brachytherapy, or radiosurgery for low-grade glioma * no prior biological therapy or chemotherapy for low-grade glioma * no other concurrent chemotherapy * no concurrent radiotherapy or biological therapy * no concurrent prophylactic growth factors * no concurrent epoetin alfa * no other concurrent investigational drugs

Keywords: adult oligodendroglioma adult mixed glioma adult diffuse astrocytoma adult pilocytic astrocytoma adult pineal gland astrocytoma
gyeongsang national university hospital registry

Conditions: Percutaneous Coronary Intervention; Hemostatic Disorder; Blood Clot

Summary: the g-nuh registry is a two-center, real-world registry of percutaneous coronary intervention in patients with significant coronary artery disease. from january 2010, pci-treated patients from gyeonsang national university hospitals (jinju \& changwon) were enrolled in this registry. the aim of this registry is to investigate long-term clinical outcomes and predictors of adverse outcomes after percutaneous coronary intervention from the academic hospitals.

in the g-nuh registry, the investigators have collected and measured multiple hemostatic, physiologic and laboratory measurements (on-admission \& 1-month) and questionnarred from pci-treated patients. this registry will focus on the impacts of these parameters on long-term clinical outcomes from east asian patients.

Eligibility criteria:
inclusion criteria: * age \>= 18 years * significant coronary artery disease * treated with pci * multiple hemostatic or physiologic measurements exclusion criteria: * medically treated cases

Keywords: east asian paradox
opioid-free anesthesia protocol for neurosurgical supratentorial tumor resection

Conditions: Supratentorial Tumors

Summary: opioids have many side effects, such as constipation, urinary retention, itchy skin, respiratory depression, and postoperative nausea and vomiting. these side effects can lead to delayed recovery, longer hospital stays, and increased health care costs. opioid-free anesthesia is the combination of anti-nociceptive drugs to block the different pathways involved in the transmission of nociceptive information, control pain, avoid opioid-related adverse reactions, and promote patient recovery. at present, opioid-free anesthesia is not widely used in craniocerebral surgery in neurosurgery, and the relevant clinical data are extensive. therefore, the investigators urgently need to conduct a randomized controlled study to provide clinical evidence for the efficacy and safety of opioid-free anesthesia in neurosurgical patients.

data sharing plan: the deidentified participant data reported in this study could be made available to researchers upon approval by the corresponding author (dr. ruquan han, ruquan.han@ccmu.edu.cn) immediately after publication. the reasonable request should provide a formal protocol for database use that has been approved by the ethics institutions.

Eligibility criteria:
inclusion criteria: * scheduled to undergo craniotomy for supratentorial tumors with general anesthesia; * 18 years≤age≤65 years; * american society of anesthesiologists (asa) physical status of i to iii; * signed informed consent. exclusion criteria: * patients with a body mass index (bmi)≥35 kg/m2; * patients with severe hepatic and renal insufficiency; * patients with cognitive dysfunction, aphasia and other states that do not cooperate with the assessment; * preoperative magnetic resonance imaging of the head showed midline displacement \>5 mm; * patients undergoing electrophysiological monitoring during surgery; * pregnant or lactating patients.
enhancing memory to facilitate weight loss: tracking, recording and coaching

Conditions: Overweight and Obesity

Summary: the objective of this application is to pilot test and evaluate the acceptability and efficacy of a program to facilitate weight loss by enhancing memory for a recently consumed meal.

once enrolled, all participants will receive behavioral weight loss treatment. treatment will be 12 weeks in duration and will consist of 7 sessions. the content of sessions will provide the main elements described in behavioral therapy programs for obesity, based on empirical literature. participants will be provided handouts, and the handout content will be based on our clinic treatment manual and published behavior therapy protocols. the program will be administered in individual 30-60-min sessions with a behavioral coach meeting every other week. this program emphasizes self-monitoring of food intake. it also emphasizes gradual weight loss, increasing physical activity, and improving diet through permanent lifestyle changes. program topics include: self-monitoring of eating behavior, physical activity, changing the home environment and nutrition education. all treatment sessions will be conducted by licensed clinical health psychologists or psychology doctoral level students with experience in leading weight loss interventions.

Eligibility criteria:
inclusion criteria: 1. participant must be overweight (bmi between 25-40) 2. participant must be between the ages of 18-55 3. participant can read at a minimum of an 5th grade level in english 4. participant is willing to participate and to commit to 12 weeks of treatment and attendance at assessments exclusion criteria: 1. participant is unable to exercise (ex., due to physical or medical reasons) 2. major psychiatric disorder diagnoses, including an eating disorder 3. diagnoses of a serious current physical disease (such as diabetes) for which physician supervision of diet is needed 4. participant who takes medications that would influence weight and eating, or cognitive functioning, such as attention, concentration, or mental status
the association of cognitive distortions and ncds among users of medical internet resources

Conditions: Cognitive Biases; Non-infecious Chronic Disease

Summary: currently, medical internet resources are popular among the population of most countries, including russia. so its can be used as a platform for mass measures of prevention. now we can receive a lot of information about socio-demographic characteristics, risk factors and the presence of chronic non-infectious diseases among users of medical internet resources. and these knowledges are necessary to create effective online interventions for prevention of the most common diseases. we have enough resources to identify and control risk factors for chronic non-infectious diseases. but adherence to doctor's recommendations remains at a low level. working with cognitive biases is one of the points of application for increasing adherence to treatment and the rules of a healthy lifestyle. certain groups of patients have special cognitive biases. we assume that creation a typical portrait of a patient can reveal relationships and factors the variant of cognitive biases. this information may help to more effectively carry out preventive work with users of medical internet resources, forming the correct patterns of perception and thereby improving adherence to the doctor's recommendations.


Eligibility criteria:
inclusion criteria: * user of medical internet resources older 18 years exclusion criteria: * none
a chinese herbal medicine for ibs-c

Conditions: Constipation-predominant Irritable Bowel Syndrome

Summary: this double-blind, placebo-controlled randomized pilot clinical trial will test the hypothesis that granules of cdd-2105, a chinese herbal medicine formula, will have efficacy in alleviating constipation and abdominal pain in individuals with ibs-c. participants (n=78) will be randomly assigned to the treatment or placebo group in a 1:1 ratio, followed by 4 weeks of intervention and 4 weeks of follow-up.

this double-blind, placebo-controlled randomized pilot clinical trial will test the hypothesis that granules of cdd-2105, a chinese herbal medicine formula, will have efficacy in alleviating constipation and abdominal pain in individuals with ibs-c. participants (n=78) will be randomly assigned to the treatment or placebo group in a 1:1 ratio, followed by 4 weeks of intervention and 4 weeks of follow-up.primary objective: to determine the efficacy and safety of cdd-2105 granules for treating ibs-c.

Eligibility criteria:
inclusion criteria: * 18-65 years adults * fulfill the clinically diagnosed with ibs-c based on the rome iv criteria * abdominal pain intensity: weekly average of the worst daily (in the past 24 hours) abdominal pain score of ≥3.0 on a 0 to 10 point scale (based on the 2-week e-diary in screening) * csbm ≤ 2 times/week (based on the 2-week e-diary in screening) * understand and be able to follow written and oral instructions in chinese * provide informed consent * able to use and complete 2-week e-diary for screening exclusion criteria: * drug-induced or secondary causes of constipation * use of medications and/or supplements that may confound the study outcomes (including but not limited to antibiotics, steroid, analgesic drug, neuromodulator, prebiotics, symbiotics, or probiotics) * clinically significant colonoscopy or sigmoidoscopy examination findings after the onset of symptoms for patients who (1) is ≥50 years old; and/or (2) has family risk of colon-rectal cancer or familial polyposis syndromes; and/or (3) has alarm symptoms within 6 months before screening (unintentional weight loss: \>10% in 3 months, blood in the stools not caused by hemorrhoids or anal fissures, fever of unknown origin, anemia) * clinically significant laboratory or imaging findings within 6 months before screening * recent history of mushy or watery stools within one month * allergic to chinese herbal medicine or g6pd * abdominal surgeries within the past year (except laparoscopic appendectomy) * pregnancy, breastfeeding or plan to become pregnant with the study timeframe * any disease(s), condition(s) or habit(s) deemed by the investigators that would compromise the individual's ability to complete the study, e.g. serious psychiatric conditions, at the discretion of the investigators * any disease(s), condition(s) or habit(s) deemed by the investigators that would prevent participation in the study, e.g. participation in past or active clinical research, at the discretion of the investigators

Keywords: chinese herbal medicine ibs-c
pharmacist counseling on the health-related quality of life of patients with type 2 diabetes mellitus

Conditions: Type 2 Diabetes Mellitus

Summary: the quality of life (qol) of patients with type 2 diabetes mellitus (t2dm) is a measure of the successful outcomes of therapy. the program of management of chronic diseases "program pengelolaan penyakit kronis" (prolanis) among patients with hypertension and t2dm is a new strategy of the badan penyelenggara jaminan sosial (bpjs), which is the indonesian national health insurance system. the impact of pharmacist counseling interventions on health-related qol (hrqol) was analyzed in prolanis t2dm patients.

a cluster randomized controlled trial that was designed to include two groups (control (n = 111) and intervention (n = 109) groups), and pre- and post-test procedures were conducted. the participants were prolanis t2dm patients who attended four primary health-care centers (puskesmas) in makassar city, south sulawesi, indonesia from august 2017 to august 2018. the intervention group received systematic counseling for 6 months. the data were collected using the bahasa indonesia version of the european quality of life 5 dimensions 5 levels (eq-5d-5l) questionnaire and were analyzed using eq-5d preference weight for each health state with the indonesian eq-5d-5l value set. furthermore, the eq-5d index and the eq-5d vas score were calculated and hba1c levels were assessed.

Eligibility criteria:
inclusion criteria: * registration in the prolanis at bpjs makassar city, * age between 20 and 65 years, * hba1c level ≥6.5%, and * willingness to participate in research by signing an informed consent (for all t2dm patients with or without comorbidities) exclusion criteria: * irregular control schedules, * incomplete medical record data, * circumstances that did not allow filling out the questionnaires (e.g., inability to speak, see, or hear)
mechanisms of acute asthma exacerbations through molecular analysis of airway secretions and tissues

Conditions: Asthma

Summary: the purpose of this study is to investigate mechanisms which cause acute asthma exacerbations by examining blood and airway secretions during an acute onset (sputum or tracheal aspirates). this pilot study is intended to uncover new mechanisms of asthma exacerbation and to generate hypotheses for future study. by collaborating with genentech, we (scientists at ucsf) plan to incorporate the latest scientific findings into our work to discover and develop new treatments for asthma.

asthma is a common airway disease with persistent unmet needs in terms of treatment. although many asthmatics enjoy good control of their disease by using regularly scheduled corticosteroid treatment, a significant minority do not achieve optimal control with steroids and suffer asthma exacerbations which can be severe and even fatal. asthma pathophysiology is complex and involves multiple cell types and multiple signaling mechanisms. one approach to this complexity has been to study responses of isolated airway cells to experimental conditions which model asthmatic inflammation; another has been genetic manipulations of candidate mediators of asthma in inbred mice. these studies have yielded important insights about possible mechanisms of asthma in humans, but the relevance of these mechanisms to human disease has not always been proven, and it is possible that unsuspected mechanisms have not yet been revealed by these approaches. in the current study, we propose to collect samples of airway secretions and blood from asthmatic subjects when their asthma is uncontrolled and they are being treated in the hospital or emergency room. our goal will be to identify abnormal gene expression profiles and protein concentration abnormalities in these biological fluids. we will then study them again 6-10 weeks later when their asthma is controlled. this study design will allow us to compare airway and blood biomarkers of asthma exacerbation during acute asthma and recovery. "

Eligibility criteria:
inclusion criteria: 1. male and female subjects aged 18 - 70 years 2. medical history of asthma 3. currently experiencing an acute exacerbation of asthma 4. ability to provide informed consent or have a surrogate provide consent. 5. ability to provide sputum. exclusion criteria: 1. cigarette smoking: subjects must be non-smokers. non-smokers are defined as subjects who have never smoked or who have not smoked for 1 year and have a total pack-year smoking history \< 10 packs. 2. pregnant women.

Keywords: acute asthma
combination of capecitabine and oxaliplatin in patients with relapsed or refractory gastric cancer

Conditions: Gastric Cancer

Summary: the purpose of this study is to evaluate the efficacy and overall survival of the regimen of xelox (xeloda and oxaliplatin combination) in the patients with relapsed and refractory gastric cancer.

the result of treatment in relapsed and refractory gastric cancer is still not satisfactory. for the moment, the combination of 5-fu and cisplatin is regularly used. capecitabine and oxaliplatin are new generation drugs of 5-fu and cisplatin. the current study is to evaluate the efficacy and toxicity of this combination.

Eligibility criteria:
inclusion criteria: * age between 18 and 70 years * patients with histologically confirmed, unresectable, recurrent and/or metastatic gastric adenocarcinoma * ecog performance status ≤1 * measurable diseases according to the recist * relapse or refractory after the first-line chemotherapy * sign icf,normal laboratory findings:absolute neutrophil count and platelet count ≥ 2.0×109/l and 80×109/l, respectively, hepatic function (total serum bilirubin ≤ unl, transaminases ≤ 1.5 times upper normal limit) and renal function (calculated creatinine clearance ≥ 60 ml/min). exclusion criteria: * relapse within 6 months after adjuvant chemotherapy which contained oxaliplatin * have used any of drugs in the regimen in first-line chemotherapy * pregnant or lactating women,serious uncontrolled diseases and intercurrent infection * the evidence of cns metastasis * history of other malignancies except cured basal cell carcinoma of skin and carcinoma in-situ of uterine cervix * received other chemotherapy regimen after metastasis * participated in other clinical trials.

Keywords: advanced gastric cancer response rate side effects time to progression overall survival